- Personalized management of cirrhosis by non-invasive tests of liver fibrosis
-
Wong GL, Espinosa W, Wong VW
- KMID: 2351019
- Clin Mol Hepatol.
- 2015 Sep;21(3):200-211.
- doi: 10.3350/cmh.2015.21.3.200
Owing to the high prevalence of various chronic liver diseases, cirrhosis is one of the leading causes of morbidity and mortality worldwide. In recent years, the development of non-invasive tests... -
- CITED
-
- Close
- SHARE
-
- Close
- Tips for Responding to Reviewers' Comments–from an Editor's or Reviewer's Points of View
-
Wong GL
- KMID: 2434384
- Gut Liver.
- 2019 Jan;13(1):7-10.
- doi: 10.5009/gnl18361
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
-
Wong GL
- KMID: 2417057
- Clin Mol Hepatol.
- 2018 Jun;24(2):108-113.
- doi: 10.3350/cmh.2017.0068
The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of fibrosis progression in chronic viral hepatitis
-
Wong GL
- KMID: 2069758
- Clin Mol Hepatol.
- 2014 Sep;20(3):228-236.
- doi: 10.3350/cmh.2014.20.3.228
Prediction of liver fibrosis progression has a key role in the management of chronic viral hepatitis, as it will be translated into the future risk of cirrhosis and its various... -
- CITED
-
- Close
- SHARE
-
- Close
- Unmet need in chronic hepatitis B management
-
Liang LY, Wong GL
- KMID: 2451920
- Clin Mol Hepatol.
- 2019 Jun;25(2):172-180.
- doi: 10.3350/cmh.2018.0106
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral... -
- CITED
-
- Close
- SHARE
-
- Close
